Merck sales disappoint as Januvia, Remicade fall short

By Reuters

Merck & Co Inc (MRK.N) on Thursday reported lower-than-expected quarterly revenue, hurt by disappointing sales of its Januvia diabetes treatment and Remicade arthritis drug.

But the second largest U.S. drugmaker beat first-quarter earnings forecasts because of cost controls and a weakening dollar, and it slightly raised its full-year profit outlook.

Combined sales of Januvia and a related combination medicine called Janumet edged up 1 percent to $1.41 billion, $30 million shy of Wall Street expectations. Demand for the drugs, Merck’s biggest franchise and former sparkplugs for company growth, has waned due to new competition, including from Eli Lilly & Co’s (LLY.N) Jardiance and other members of a family of medicines called SGLT-2 inhibitors.

Remicade sales fell 30 percent to $349 million, $25 million below forecasts. The injectable treatment for rheumatoid arthritis faces escalating competition in Europe from cheaper biosimilars.

A bright spot in the earnings report was Keytruda, a new cancer treatment that works by taking the brakes off the immune system. Its sales rose to $249 million from $83 million a year earlier, slightly above expectations.

But Keytruda sales are ramping up more slowly than those of Bristol-Myers Squibb Co’s (BMY.N) similar new immuno-oncology product called Opdivo, which also treats melanoma and lung cancer and is being tested for an array of other types of cancer. Its sales jumped to $704 million in the quarter.

For Merck, “pressure on important marketed products such as Januvia and Remicade will likely limit near-term growth opportunities” and offset faster-growing products like Keytruda, Credit Suisse analyst Vamil Divan said in a research note. Sales of animal health products were flat at $829 million, about $20 million below Wall Street forecasts, but would have risen 9 percent if not for the weakening dollar, which reduces sales outside the United States, Merck said.

Total revenue slipped 1 percent to $9.31 billion, below the average estimate of $9.46 billion among analysts surveyed by Thomson Reuters I/B/E/S.

Net income rose to $1.12 billion, or 40 cents per share, from $953 million, or 33 cents per share, a year earlier.

Excluding special items, Merck earned 89 cents per share, beating Wall Street expectations by 4 cents.

Merck raised its full-year earnings forecast to a range of $3.65 to $3.77 per share from its prior outlook of $3.60 to$3.75. It increased the low end of its sales forecast to $39.0 billion from $38.7 billion while keeping the top end at $40.2 billion.



Latest posts

Russia reopens bond market to non-hostile investors

Christine Muchira

J&J to replace talc-based powder after cancer lawsuits

Ronald Owili

UN trade body calls for halting cryptocurrency rise in developing countries

Christine Muchira

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More